Skip to main content
    E

    Edwards Lifesciences Corp (EW)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $107.11
    -0.04 (-0.04%)

    Market Cap: $61.61B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Edwards Lifesciences Corp (EW) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Edwards Lifesciences (EW) to earn $3.01 per share in the fiscal year ending Dec 31, 2026, on revenue of $6.81B. Of 30 analysts, 23 rate the stock Buy or Strong Buy, 7 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 30 ratings average 2.07, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 77% of the ratings.

    RatingAnalystsShare
    Strong Buy516.7%
    Buy1860.0%
    Hold723.3%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    30

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus rises 12.6% and revenue estimates rise 9.8%.

    Fiscal year ending Dec 31, 2026
    $3.01
    EPS consensus, revenue $6.81B
    Fiscal year ending Dec 31, 2027
    $3.39
    EPS consensus, revenue $7.48B
    Next report
    Feb 8, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$3.01$2.97 to $3.0529$6.81B$6.72B to $6.86B27
    Dec 31, 2027$3.39$2.99 to $3.4929$7.48B$7.26B to $7.71B28

    Quarterly Estimates

    The EPS consensus rises from $0.69 for the quarter ending Dec 31, 2026 to $0.84 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$0.69$0.63 to $0.7928$1.76B$1.66B to $1.88B29
    Mar 31, 2027$0.84$0.77 to $0.9019$1.80B$1.77B to $1.84B18

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 6 upward and 6 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202610
    Fiscal year ending Dec 31, 202721
    Quarter ending Mar 31, 202735

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 0.3% from $3.00.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$3.01$3.00$3.00$3.00$3.00+0.5%
    Fiscal year ending Dec 31, 2027$3.39$3.38$3.38$3.38$3.38+0.3%
    Quarter ending Mar 31, 2027$0.84$0.83$0.83$0.83$0.83+1.2%

    Frequently Asked Questions About EW

    What is the EW stock forecast?

    Consensus analyst estimates put Edwards Lifesciences's EPS at $3.01 for the fiscal year ending Dec 31, 2026, on revenue of $6.81B. The consensus rating from 30 analysts is Buy.

    How do analysts rate EW stock?

    Of 30 analysts covering Edwards Lifesciences, 5 rate it Strong Buy, 18 Buy, 7 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from EW next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $3.01, with estimates from $2.97 to $3.05 from 29 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $3.39, with estimates from $2.99 to $3.49 from 29 analysts.

    What revenue do analysts expect from Edwards Lifesciences next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $6.81B, with estimates from $6.72B to $6.86B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $7.48B, with estimates from $7.26B to $7.71B.

    How many analysts cover EW?

    30 analysts rate Edwards Lifesciences stock, and 29 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.